43 results about "Intractable epilepsy" patented technology

The invention discloses ketogenic nutritional powder applied to ketogenic therapy on patients suffering from intractable epilepsy. The ketogenic nutritional powder comprises the following components as per parts by weight: 69.45 to 72 parts of fat, 7.2 to 10 parts of protein, 8 to 14 parts of carbohydrate, 4.5 to 5 parts of mineral salt and less than 2 parts of emulsifying agent, flavoring agent and thickening agent, wherein the fat comprises plant oil; the protein comprises plant protein, animal protein, soybean oligopeptide and immune globulin; the carbohydrate comprises soluble dietary fiber and bifidus factor; and the weight ratio of the fat to the sum of the protein and the carbohydrate is (3.2-4.0):1. Due to addition of the immune globulin, the soybean oligopeptide, the dietary fiber and the bifidus factor, the ketogenic nutritional powder can effectively adjust the intestine health of the patients, can enhance the immunity of the patients, and has a good absorption and utilization effect in the bodies of the patients.

A method for functionally identifying an epileptogenic focus in pre-surgical evaluation in affected subjects with intractable epilepsy is described, the method including the delivery of an effective dose of a botulinum neurotoxin (BoNT) to a presumptive epileptogenic focus in the disease-compromised central nervous system of a mammal, under conditions whereby the effective dose of the botulinum neurotoxin interacts with the soluble N-ethylmaleimide-sensitive factor-attachment receptor (SNARE) proteins, thus impairing neurotransmission.

The present invention relates to the field of medicines, and in particular discloses a child tuberous sclerosis treatment drug including rapamycin, the child tuberous sclerosis includes child tuberous sclerosis combined intractable epilepsy, child tuberous sclerosis combined cardiac rhabdomyoma, child tuberous sclerosis combined depigmentation, facial steatadenoma, and child tuberous sclerosis combined renal angioleiomyolipoma, and the drug use method is as follows: the initial dose of the rapamycin is 1mg / (m2.d), and the blood drug concentration is maintained at 5-10ng / mL.

The invention relate to a ketogenesis mixture preparation applicable for treating refractory epilepsy, which is characterized in that: (1) fat, protein and carbohydrate form the basic prescription, a small amount of essential vitamins, minerals and aminophenol promoting the growth and the development of the human body and brain and promoting the metabolism are added in the basic prescription; (2) in the basic preparation, the weight percentages of the components are respectively that: fat 70-80 percent, protein 15-20 percent, carbohydrate 5-10 percent; (3) the physical states of all the components in the basic preparation are powder, ointment, aqua, or solid state agent. The physical states of the ketogenesis mixture preparation are powder granule, electuary, liquid agent, tablet, capsule or other solid state agent. The ketogenesis mixture preparation aims at the special nutrition requirement of Chinese, nutritional ingredient promoting the development of the brain and the metabolism is added in, the curative efficiency on refractory epilepsy reaches 80 percent, which reaches or exceeds the curative effect of the equivalent product abroad.

The present invention relates to epilepsy-inducing brain somatic mutations which are associated with intractable epilepsy caused by malformations of cortical development, and uses thereof. More particularly, the present invention relates to an mTOR (Mammalian target of rapamycin) gene having mutations in a nucleotide sequence or an mTOR protein having mutations in an amino acid sequence resulting from the mutations in the nucleotide sequence. Further, the present invention relates to a technique for diagnosing intractable epilepsy caused by malformations of cortical development using the gene or the protein.

The invention belongs to the field of research and development of polypeptide medicines and discloses a scorpion venom heat-resistant synthetic peptide and application thereof. An amino acid sequence of an SVHRP (scorpion venom heat-resistant peptide) is detected out from BmK (Buthus martensii Karsch) which is a traditional Chinese medicine; according to animal experiment verification, a scorpion venom heat-resistant peptide extract liquid sample has pharmacological activity in prevention and treatment of intractable epilepsy, Parkinson's disease and Alzheimer's disease, the sample is subjected to LaGm composite and repeated fast magnetic separation prior to nanoLC-ESI-MS (nano-liter reversed-phase chromatography and electrospray ionization mass spectrometry) integrated mass spectrometry parallel experiment to detect out a polypeptide sequence formed by 15 amino acid residues. The scorpion venom heat-resistant synthetic peptide is prepared by solid-phase chemical synthesis, chromatography purification and mass spectrometry identification. An amino acid sequence of the scorpion venom heat-resistant synthetic peptide is as shown in SEQ ID NO.1 and keeps pharmacological activity and safety of the scorpion venom heat-resistant peptide, and the scorpion venom heat-resistant peptide also has a characteristic of biological activity in promotion of reverse differentiation of neuroglial cells into neural stem cells.

The invention relates to application of SB202190 in preparation of medicines for treating intractable epilepsy. By utilizing an intractable epilepsy animal model, due to a series of researches, the SB202190 can reduce the expression of multidrug transporter-P glycoprotein (PGP) related to drug tolerance in the brain of an intractable epilepsy rat, the drug concentration of antiepileptic drugs (AEDs) in hippocampus cell extracellular fluid of the intractable epilepsy rat is improved, the AEDs is assisted to improve the electrophysiological activity of the rat, and the ignition post-attack classification is reduced, namely the drug tolerance of the intractable epilepsy can be improved by the SB202190. The application of the SB202190 is widened, and an effective way is provided for treatment of the intractable epilepsy.

The invention belongs to the biological medicine field, and relates to a pharmaceutical composition for targeting treatment of intractable epilepsy, the pharmaceutical composition of the present invention contains a micromolecule compound or a monoclonal antibody or virus vector carrying micromolecule interference RNA, the effective dosage of the micromolecule compound or the monoclonal antibody or the viral vector carrying micromolecule interference RNA in the composition on the P-glycoprotein expression inhibition efficiency can reach 30% or more than 30%, the animal experiment result shows that the effective dosage can perform the effects for inhibiting the epilepsy attack frequency and the attack duration. The corresponding brain wave presents the similar change with the epilepsy attack frequency and the attack duration.

Provided is a use of the prophylaxis, amelioration or therapy of intractable epilepsy, for example, Focal Cortical Dysplasia (FCD).

The invention discloses a pharmaceutical composition for treating intractable epilepsy and application thereof. The active components of the pharmaceutical composition comprise sodium valproate or divalproex sodium and ethambutol or medicinal salt thereof. The pharmaceutical composition has the advantages that the fact that low-dose ethambutol hydrochloride has an anti-epileptic effect is discovered for the first time, the ethambutol hydrochloride is combined with the sodium valproate or divalproex sodium to treat the intractable epilepsy, the pharmaceutical composition is evident in anti-epileptic effect, and the toxic and side effects of the pharmaceutical composition are lowered evidently.

The invention relates to a parenteral ketogenic nutrient solution and a preparation method thereof. The nutrient solution is prepared from in per 100 mL of injection water, by mass, 1.80-3.3 g of amino acid, 6.5-8.0 g of fatty substances, 0.2-0.7 g of glucose, 28.93 mg of vitamins, 327.33 mg of mineral substances, 1.32-1.49 g of an emulgator and 2.34-4.29 mmol of sodium acetate, and all the substances are dissolved in the injection water. According to the formula of the high-fat low-sugar low-amino acid nutrient solution, the nutrient solution is used for well treating intractable epilepsy andother hereditary metabolic diseases such as glucose carrier deficiency disease, pyruvate dehydrogenase deficiency disease and part of tumors and fills the gap of a parenteral ketogenic nutrient solution technology.

The invention belongs to the biological medicine field, and relates to a method for screening medicines, and concretely relates to a method for screening a sensitive type intractable epilepsy medicine. According to the invention, an epilepsy animal model capable of generating repeatedly spontaneous epileptic seizure is established, the medicine sensitive type and the medicine resistant subgroup are screened by providing the epilepsy animal model anti-epileptic medicine, and the sensitive type intractable epilepsy medicine can be screened according to the expression difference of the corresponding risk factors. The invention provides a novel treatment target and a solution method for solving the problems of drug effect reduction for intractable epilepsy presented in a present clinical application.

The invention relates to an application of 17-allylamine-17-demethoxygeldanamycin in preparation of medicine for treating epilepsy, wherein preferably, epilepsy is intractable epilepsy, and more preferably is temporal lobe epilepsy which is ineffectively treated by medicines. According to the invention, 17-allylamine-17-demethoxygeldanamycin is realized by up regulation of G1t1 protein in brain tissue. 17-allylamine-17-demethoxygeldanamycin is employed for effectively treating temporal lobe epilepsy which is ineffectively treated by medicines, simultaneously, other physiological states of a subject can not be influenced during a treatment period.

The invention discloses a screening reagent box for intractable epilepsy. The screening reagent box for the intractable epilepsy comprises an optional reagent used for detecting the expression level of micro RNA-153. The invention further discloses an application of the optional reagent used for detecting the expression level of the micro RNA-153 in preparing a reagent used for screening the intractable epilepsy. According to the reagent box, the expression level of the micro RNA-153 is detected, the risk of suffering from the intractable epilepsy for crowds to be examined can be judged, the reagent box can be used for auxiliary diagnosis of clinical intractable epilepsy, an effective base is provided for a patient to take relevant treatment measures or decisions, and a good clinical application prospect is achieved.

System and method for treating intractable epilepsy are provided. The method includes implanting electrodes in pedunculopontine nucleus and delivering electrical pulses to the pedunculopontine nucleus, thereby inducing the stimulation of cholinergic neurons leading to the release of acetylcholine, thereby enhancing the genesis of rapid eye movement sleep, which reduces the occurrence of epileptic attacks and also chronically suppresses the epileptogenic process.

The invention discloses a pharmaceutical preparation for treating intractable epilepsy, the preparation comprises a cannabis sativa extract, a gastrodia elata extract, succinylated protein, borneol and an auxiliary agent, the active ingredient of the cannabis sativa extract is a compound with an alkyl resorcinol structure, and the active ingredient of the gastrodia elata extract is a compound with an alkyl resorcinol structure. As an extraction substance which is extracted from a cannabis sativa plant and has the same biological activity, the pharmaceutical preparation has a great synergistic effect on playing a pharmacological effect on refractory epilepsy, and the pharmacological activity of the pharmaceutical preparation is effectively improved; the gastrodia elata extract can provide effective nutrition and repair nerves in the brain, and the borneol can be used as a channel guiding drug to enhance absorption of other drugs in a blood brain barrier and effectively relieve convulsion, spasm, unconsciousness, wandering and other clinical characteristics accompanied by epilepsy disease attack, the succinylated protein in the preparation can prevent the drug from being damaged in an acid environment, and the nano-emulsion preparation prepared by adding the succinylated protein can effectively improve the bioavailability and stability of the drug.

The invention discloses a medicine for treating intractable epilepsy and a preparation method thereof, the medicine comprises a cannabis sativa extract, a gastrodia elata extract and borneol, the effective component of the cannabis sativa extract is a compound which is separated and extracted from cannabis sativa and has an alkylresorcinol structure, the medicine has a great synergistic effect on playing a pharmacological effect on intractable epilepsy, and the pharmacological activity of the pharmaceutical composition is effectively improved; the gastrodia elata extract can provide effective nutrition and repair nerves in the brain, the borneol can be used as a channel guiding drug to enhance absorption of other drugs in a blood brain barrier and effectively relieve convulsion, spasm, unconsciousness, wandering and other clinical characteristics accompanied by epilepsy disease attack, and the three drug components are subjected to traditional Chinese medicine prescription compatibility, and the intractable epilepsy is effectively treated in a targeted manner from three aspects of pathological treatment of epilepsy diseases, nutrition and repair of damaged nerves in the brain and relieving of clinical characterization.

The invention discloses application of a benzodifuranone compound in preparation of medicines for treating intractable epilepsy, and belongs to the technical field of medicines. According to the application, the benzodifuranone compound is used for treating epilepsy for the first time, and particularly a new candidate drug is provided for treatment of intractable epilepsy. In addition, the invention further provides a compound medicine combining the benzodifuranone compound and sodium valproate, and the benzodifuranone compound and the sodium valproate have an obvious synergistic effect in treatment of intractable epilepsy diseases.

Deep brain stimulation of the ventral pallidum (VP-DBS) prevents or potently attenuates epileptiform activity and behavioral seizures. VP-DBS prior to pilocarpine prevented behavioral partial and generalized forebrain seizures and generalized brainstem seizures in most animals. VP-DBS after brainstem seizures emerged prevented or reduced the appearance of subsequent behavioral and electrographic brainstem seizures. Even if VP-DBS was turned on after partial forebrain seizures started, this timed approach could still reduce partial forebrain seizures but also prevented secondarily generalized forebrain seizures. Epileptiform activity in brainstem areas, especially in the nucleus of the solitary tract (NTS) which controls cardiovascular function, was prevented by VP-DBS. Altogether, VP-DBS is a therapeutic approach for individuals with intractable epilepsy with partial and/or generalized seizures and may potentially prevent or diminish sudden unexpected death in epilepsy (SUDEP) by preserving activity of brain stem neurons involved in cardio-respiratory function.

The invention discloses a construction method of a zebra fish intractable epilepsy model. A mutant human GABRG2 gene of which the 282th proline codon is mutated into serine is transferred into a zebrafish, so that the zebra fish becomes a zebra fish line with intractable epilepsy phenotype. The method provides an effective method basis for construction of the zebra fish intractable epilepsy model, also provides an important tool for epilepsy pathology research and antiepileptic drug screening research, and has great foundation and clinical research application value.